LGD4033

    • LGD4033

    The SARM LGD-4033, also known as Ligandrol, has a high affinity for androgen receptors. Unlike testosterone, which exerts its anabolic effects through the same pathway, LGD-4033 is highly selective for receptors in skeletal muscle, bone, and connective tissue, with minimal affinity for receptors in the prostate, scalp, and skin.

    $85


    Contact us
    Category:

    SARMS LGD 4033

    The SARM LGD-4033, also known as Ligandrol, is a third generation nonsteroidal oral SARM with a high affinity for androgen receptors (Ki of approximately 1 nM). It is the second most popular SARM currently on the market. Unlike testosterone, which exerts its anabolic effects through the same pathway, LGD-4033 is highly selective for receptors in skeletal muscle, bone, and connective tissue, with minimal affinity for receptors in the prostate, scalp, and skin.

    It was developed by Ligand Pharmaceuticals to treat conditions such as muscular dystrophy and osteoporosis without the masculinizing side effects of anabolic steroids. Many researchers consider LGD 4033 to be the best SARM for producing lean mass. Sports Technology Labs is the best place to buy LGD-4033 online.

    LGD 4033 Benefits Clinical Studies

    Muscle Mass
    Preclinical primate data showed significant increases in lean body mass in male and female monkeys at doses of 0.6, 3, 15, or 75 mg/kg body weight over 13 weeks. In addition, 70% of the weight gain was retained after a 4-week recovery period.

    Only the 75 mg/kg group was discontinued after 48 days due to toxicity. This amount is significantly higher than the highest amount administered in clinical trials.

    Bone Recovery

    A Phase 1 clinical trial in which 76 adult males were given different doses of LGD-4033 orally showed that lean body mass increased with increasing doses and was well tolerated by all 76 subjects over 21 days. The Phase 2 clinical trial included 120 subjects recovering from hip fracture surgery. Subjects received placebo, 0.5, 1, or 2 mg of LGD-4033 over 12 weeks.

    All doses of LGD-4033 significantly increased total lean body mass, and mean fat mass decreased with increasing doses.

    Serum procollagen type 1 propeptide (s-P1NP), a marker of bone anabolic metabolism, improved in subjects treated with LGD-4033 compared with placebo, as did 6-minute walk distance. No significant adverse events were reported in any of the study groups.

    Subjects were evaluated 12 weeks after the end of the trial, during which time they maintained the muscle mass they had gained from taking the drug.